|
1
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou
XN, Chen R, Gu XY, Wei WW and He J: Report of cancer epidemiology
in China, 2015. Zhonghua Zhong Liu Za Zhi. 41:19–28. 2019.(In
Chinese). PubMed/NCBI
|
|
4
|
Marchetti C, Palaia I, De Felice F,
Musella A, Donfracesco C, Vertechy L, Romito A, Piacenti I, Musio
D, Muzii L, et al: Tyrosine-kinases inhibitors in recurrent
platinum-resistant ovarian cancer patients. Cancer Treat Rev.
42:41–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
du Bois A, Reuss A, Pujade-Lauraine E,
Harter P, Ray-Coquard I and Pfisterer J: Role of surgical outcome
as prognostic factor in advanced epithelial ovarian cancer: A
combined exploratory analysis of 3 prospectively randomized phase 3
multicenter trials: By the Arbeitsgemeinschaft Gynaekologische
Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe
d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire
(GINECO). Cancer. 115:1234–1244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zang RY, Harter P, Chi DS, Sehouli J,
Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, et
al: Predictors of survival in patients with recurrent ovarian
cancer undergoing secondary cytoreductive surgery based on the
pooled analysis of an international collaborative cohort. Br J
Cancer. 105:890–896. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ottevanger PB: Ovarian cancer stem cells
more questions than answers. Semin Cancer Biol. 44:67–71. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mirza MR, Monk BJ, Herrstedt J, Oza AM,
Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I,
et al: Niraparib maintenance therapy in platinum-sensitive,
recurrent ovarian cancer. N Engl J Med. 375:2154–2164. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee EK and Konstantinopoulos PA: Combined
PARP and immune checkpoint inhibition in ovarian cancer. Trends
Cancer. 5:524–528. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mitsuhashi Y, Horiuchi A, Miyamoto T,
Kashima H, Suzuki A and Shiozawa T: Prognostic significance of
Notch signalling molecules and their involvement in the
invasiveness of endometrial carcinoma cells. Histopathology.
60:826–837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park JT, Li M, Nakayama K, Mao TL,
Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih IeM and Wang TL:
Notch3 gene amplification in ovarian cancer. Cancer Res.
66:6312–6318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Z, Yun R, Yu X, Hu H, Huang G, Tan B
and Chen T: Overexpression of Notch3 and pS6 is associated with
poor prognosis in human ovarian epithelial cancer. Mediators
Inflamm. 2016:59534982016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jung SG, Kwon YD, Song JA, Back MJ, Lee
SY, Lee C, Hwang YY and An HJ: Prognostic significance of Notch 3
gene expression in ovarian serous carcinoma. Cancer Sci.
101:1977–1983. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park JT, Chen X, Tropè CG, Davidson B,
Shih IeM and Wang TL: Notch3 overexpression is related to the
recurrence of ovarian cancer and confers resistance to carboplatin.
Am J Pathol. 177:1087–1094. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu W, Liu T, Ivan C, Sun Y, Huang J,
Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, et al:
Notch3 pathway alterations in ovarian cancer. Cancer Res.
74:3282–3293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta N, Xu Z, El-Sehemy A, Steed H and Fu
Y: Notch3 induces epithelial-mesenchymal transition and attenuates
carboplatin-induced apoptosis in ovarian cancer cells. Gynecol
Oncol. 130:200–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Derrien T, Guigó R and Johnson R: The long
non-coding RNAs: A new (P)layer in the ‘Dark Matter’. Front Genet.
2:1072012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Y, Ishak Gabra MB, Hanse EA, Lowman
XH, Tran TQ, Li H, Milman N, Liu J, Reid MA, Locasale JW, et al:
MiR-135 suppresses glycolysis and promotes pancreatic cancer cell
adaptation to metabolic stress by targeting phosphofructokinase-1.
Nat Commun. 10:8092019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang W, Zhou W, Xiang L, Wu X, Zhang P,
Wang J, Liu G, Zhang W, Peng Y, Huang X, et al: The
p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell
proliferation in human colorectal cancer. Nat Commun. 10:6632019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang T, Wan X, Alvarez AA, James CD, Song
X, Yang Y, Sastry N, Nakano I, Sulman EP, Hu B and Cheng SY: MIR93
(microRNA-93) regulates tumorigenicity and therapy response of
glioblastoma by targeting autophagy. Autophagy. 15:1100–1111. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Z, Zhang L, Wang B, Wei R, Wang Y,
Wan J, Zhang C, Zhao L, Zhu X, Zhang Y, et al: MiR-337-3p
suppresses proliferation of epithelial ovarian cancer by targeting
PIK3CA and PIK3CB. Cancer Lett. 469:54–67. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tung CH, Kuo LW, Huang MF, Wu YY, Tsai YT,
Wu JE, Hsu KF, Chen YL and Hong TM: MicroRNA-150-5p promotes cell
motility by inhibiting c-Myb-mediated Slug suppression and is a
prognostic biomarker for recurrent ovarian cancer. Oncogene.
39:862–876. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin C and Yang L: Long noncoding RNA in
cancer: Wiring signaling circuitry. Trends Cell Biol. 28:287–301.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Klingenberg M, Matsuda A, Diederichs S and
Patel T: Non-coding RNA in hepatocellular carcinoma: Mechanisms,
biomarkers and therapeutic targets. J Hepatol. 67:603–618. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang CJ, Zhu CC, Xu J, Wang M, Zhao WY,
Liu Q, Zhao G and Zhang ZZ: The lncRNA UCA1 promotes proliferation,
migration, immune escape and inhibits apoptosis in gastric cancer
by sponging anti-tumor miRNAs. Mol Cancer. 18:1152019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H,
Kong J, Ding K, Shen HM, Wu H, et al: Long non-coding RNA linc00673
regulated non-small cell lung cancer proliferation, migration,
invasion and epithelial mesenchymal transition by sponging
miR-150-5p. Mol Cancer. 16:1182017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Du Z, Sun T, Hacisuleyman E, Fei T, Wang
X, Brown M, Rinn JL, Lee MG, Chen Y, Kantoff PW and Liu XS:
Integrative analyses reveal a long noncoding RNA-mediated sponge
regulatory network in prostate cancer. Nat Commun. 7:109822016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zheng ZQ, Li ZX, Zhou GQ, Lin L, Zhang LL,
Lv JW, Huang XD, Liu RQ, Chen F, He XJ, et al: Long noncoding RNA
FAM225A promotes nasopharyngeal carcinoma tumorigenesis and
metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and
upregulate ITGB3. Cancer Res. 79:4612–4626. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sticht C, De La Torre C, Parveen A and
Gretz N: miRWalk: An online resource for prediction of microRNA
binding sites. PLoS One. 13:e02062392018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vilming Elgaaen B, Olstad OK, Haug KB,
Brusletto B, Sandvik L, Staff AC, Gautvik KM and Davidson B: Global
miRNA expression analysis of serous and clear cell ovarian
carcinomas identifies differentially expressed miRNAs including
miR-200c-3p as a prognostic marker. BMC Cancer. 14:802014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Paraskevopoulou MD, Georgakilas G,
Kostoulas N, Reczko M, Maragkakis M, Dalamagas TM and Hatzigeorgiou
AG: DIANA-LncBase: Experimentally verified and computationally
predicted microRNA targets on long non-coding RNAs. Nucleic Acids
Res. 41((Database Issue)): D239–D245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42((Database Issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen
X, Zhang Q, Yan G and Cui Q: LncRNADisease: A database for
long-non-coding RNA-associated diseases. Nucleic Acids Res.
41((Database Issue)): D983–D986. 2013.PubMed/NCBI
|
|
39
|
Groeneweg JW, Foster R, Growdon WB,
Verheijen RH and Rueda BR: Notch signaling in serous ovarian
cancer. J Ovarian Res. 7:952014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Khan A, Fornes O, Stigliani A, Gheorghe M,
Castro-Mondragon JA, van der Lee R, Bessy A, Chèneby J, Kulkarni
SR, Tan G, et al: JASPAR 2018: Update of the open-access database
of transcription factor binding profiles and its web framework.
Nucleic Acids Res. 46:D12842018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu H, Wang G, Zhou X, Song X, Gao H, Ma
C, Chang H, Li H, Liu FF, Lu J and Ma J: miR-1299 suppresses cell
proliferation of hepatocellular carcinoma (HCC) by targeting CDK6.
Biomed Pharmacother. 83:792–797. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu LH, Tian QQ, Liu J, Zhou Y and Yong H:
Upregulation of hsa_circ_0136666 contributes to breast cancer
progression by sponging miR-1299 and targeting CDK6. J Cell
Biochem. 120:12684–12693. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Meng L, Liu S, Ding P, Chang S and Sang M:
Circular RNA ciRS-7 inhibits autophagy of ESCC cells by functioning
as miR-1299 sponge to target EGFR signaling. J Cell Biochem.
121:1039–1049. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Morgan SL, Wyant GA and Dinulescu DM:
‘Take it up a NOTCH’: Novel strategies for cancer therapy. Cell
Cycle. 12:191–192. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sang M, Meng L, Liu S, Ding P, Chang S, Ju
Y, Liu F, Gu L, Lian Y and Geng C: Circular RNA ciRS-7 maintains
metastatic phenotypes as a ceRNA of miR-1299 to target MMPs. Mol
Cancer Res. 16:1665–1675. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shah MM, Zerlin M, Li BY, Herzog TJ,
Kitajewski JK and Wright JD: The role of Notch and gamma-secretase
inhibition in an ovarian cancer model. Anticancer Res. 33:801–808.
2013.PubMed/NCBI
|
|
48
|
Chen X, Thiaville MM, Chen L, Stoeck A,
Xuan J, Gao M, Shih IeM and Wang TL: Defining NOTCH3 target genes
in ovarian cancer. Cancer Res. 72:2294–2303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Young TL, Matsuda T and Cepko CL: The
noncoding RNA taurine upregulated gene 1 is required for
differentiation of the murine retina. Curr Biol. 15:501–512. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guo S, Zhang L, Zhang Y, Wu Z, He D, Li X
and Wang Z: Long non-coding RNA TUG1 enhances chemosensitivity in
non-small cell lung cancer by impairing microRNA-221-dependent PTEN
inhibition. Aging (Albany NY). 11:7553–7569. 2019.PubMed/NCBI
|
|
51
|
Yu G, Zhou H, Yao W, Meng L and Lang B:
lncRNA TUG1 Promotes cisplatin resistance by regulating CCND2 via
epigenetically silencing miR-194-5p in bladder cancer. Mol Ther
Nucleic Acids. 16:257–271. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang Z, Wang X, Cao S, Han X, Wang Z,
Zhao X, Liu X, Li G, Pan and Lei D: The long noncoding RNA TUG1
promotes laryngeal cancer proliferation and migration. Cell Physiol
Biochem. 49:2511–2520. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Barbagallo C, Brex D, Caponnetto A,
Cirnigliaro M, Scalia M, Magnano A, Caltabiano R, Barbagallo D,
Biondi A, Cappellani A, et al: LncRNA UCA1, upregulated in CRC
biopsies and downregulated in serum exosomes, controls mRNA
expression by RNA-RNA interactions. Mol Ther Nucleic Acids.
12:229–241. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
He C, Liu Z, Jin L, Zhang F, Peng X, Xiao
Y, Wang X, Lyu Q and Cai X: lncRNA TUG1-mediated miR-142-3p
downregulation contributes to metastasis and the
epithelial-to-mesenchymal transition of hepatocellular carcinoma by
targeting ZEB1. Cell Physiol Biochem. 48:1928–1941. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sun J, Hu J, Wang G, Yang Z, Zhao C, Zhang
X and Wang J: LncRNA TUG1 promoted KIAA1199 expression via miR-600
to accelerate cell metastasis and epithelial-mesenchymal transition
in colorectal cancer. J Exp Clin Cancer Res. 37:1062018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xu Y, Ge Z, Zhang E, Zuo Q, Huang S, Yang
N, Wu D, Zhang Y, Chen Y, Xu H, et al: The lncRNA TUG1 modulates
proliferation in trophoblast cells via epigenetic suppression of
RND3. Cell Death Dis. 8:e31042017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kuang D, Zhang X, Hua S, Dong W and Li Z:
Long non-coding RNA TUG1 regulates ovarian cancer proliferation and
metastasis via affecting epithelial-mesenchymal transition. Exp Mol
Pathol. 101:267–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li TH, Zhang JJ, Liu SX and Chen Y: Long
non-coding RNA taurine-upregulated gene 1 predicts unfavorable
prognosis, promotes cells proliferation, and inhibits cells
apoptosis in epithelial ovarian cancer. Medicine (Baltimore).
97:e05752018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chen LL: Linking long noncoding RNA
localization and function. Trends Biochem Sci. 41:761–772. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ren K, Li Z, Li Y, Zhang W and Han X: Long
noncoding RNA taurine-upregulated gene 1 promotes cell
proliferation and invasion in gastric cancer via negatively
modulating miRNA-145-5p. Oncol Res. 25:789–798. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang Y, Yang T, Zhang Z, Lu M, Zhao W,
Zeng X and Zhang W: Long non-coding RNA TUG1 promotes migration and
invasion by acting as a ceRNA of miR-335-5p in osteosarcoma cells.
Cancer Sci. 108:859–867. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhao L, Sun H, Kong H, Chen Z, Chen B and
Zhou M: The lncRNA-TUG1/EZH2 axis promotes pancreatic cancer cell
proliferation, migration and EMT phenotype formation through
sponging miR-382. Cell Physiol Biochem. 42:2145–2158. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sheng Q, Zhang Y, Wang Z, Ding J, Song Y
and Zhao W: Cisplatin-mediated down-regulation of miR-145
contributes to up-regulation of PD-L1 via the c-Myc transcription
factor in cisplatin-resistant ovarian carcinoma cells. Clin Exp
Immunol. 200:45–52. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tan H, He Q, Gong G, Wang Y, Li J, Wang J,
Zhu D and Wu X: miR-382 inhibits migration and invasion by
targeting ROR1 through regulating EMT in ovarian cancer. Int J
Oncol. 48:181–190. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y,
Fang Y, Lin X, Xu Y, Xu W, et al: miR-145 sensitizes ovarian cancer
cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer.
135:1286–1296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Katsushima K, Natsume A, Ohka F, Shinjo K,
Hatanaka A, Ichimura N, Sato S, Takahashi S, Kimura H, Totoki Y, et
al: Targeting the Notch-regulated non-coding RNA TUG1 for glioma
treatment. Nat Commun. 7:136162016. View Article : Google Scholar : PubMed/NCBI
|
